Stock Money Flow
About Money Flow
Money flow gives a snapshot of relative buying and selling pressure in a stock.
A ratio above one suggests greater buying pressure, below one suggests greater selling.
See more in "Help."
Uptick/Downtick Trade Ratio
Net Money Flow+ $50,044
A stock with a 50 million market cap with a NDA filed and a phase 3 trial going on and 23 million cash no debt and other trials in phase 2 . There is none. That is why smart money is accumulating. This is a steal.
Since AEZS-108 is a delivery system that if it can deliver a drug to a fight a certain cancer that it could be used with any drug for that cancer not just the one they are testing. If so that would be worth billions. Nov update on AEZS website. Also Oct update on perifosine for glioma on gov trials. With so little cancer drugs being developed large pharma looks at every one very closely. With 108 in phase 3 there might be a big interest in AEZS.
Huge volume, 18% higher price yesterday. Today will beat daily volume in first 1/2 hour. Have a feeling good news soon. This spike isn't caused buy all these new pumpers. They are just joining on the band wagon.
I never said they filed the NDA 3 years ago. Get a girlfriend or a dog your obsession with AEZS is bizarre. All you do is say the same thing over and over again in different words. Spending all this energy on a small cap stock is not normal. Wondering what the real reason is since you stated you own no AEZS stock? I don't buy your reasoning that you want to save us money.
You are right Engel said that they would file the NDA in 2011 but that was before the FDA said they have to add more subjects to the study. Look at press release 7/26/2011. Final results were 6/26/2012. After that they got the patents. Who is going to file an NDA with no patent protection. So i say your statement is very misleading.
The final results for AEZS-130 were published 10/18/2012. AEZS-130 received the U.S.patent on 8/7/12 and the European patent 9/25/2012. Some on this board are saying it is 3 years AEZS was applying for a NDA. That is not true. Also saying that AEZS filed the NDA knowing something is wrong with the test is absurd. AEZS got a SPA from the FDA for AEZS-108 on12/29/2012 for endometrial cancer. They started working on this trial fast and received 10 million towards its trial. As for AEZS-108 in bladder cancer Dodd stated in the cc call " Phase II trial in bladder cancer. In that regard, we're currently reviewing our options with this trial simply because we want to make sure we are utilizing all of our resources appropriately. And where we are developing in the clinic, we have enough resources to progress that in a timely manner." I take that to mean that the clinical trial is to small and not going fast enough and they might expand it.. Maybe that would be available for a partnership. This stock like many other bios has seen it's share of pain. I am not defending its past mistakes but as someone infers they were deliberate to line their pockets is absurd. With the price at $1.35, 23 million cash, pipeline in AEZS-108 and AEZS-130 and new management, this stock could rise substantially from these low levels. The FDA by giving a a SPA to AEZS believes the science is sound. They wouldn't allow to use the sick and dying for personal profit as dsco suggests. As for dilution, if AEZS-108 and 130 pans out they will need more money but the stock price will be higher. Just like KERX when the diluted in Jan this year. As I mentioned before this stock seems to be under accumulation due to the large bids being filled with small sales.
Some institution sees the value of AEZS at these bargain basement prices.
After reading this maybe AEZS-108 for bladder cancer will be for sale. Conclusions: This is the first case of a patient with LHRH-R positive Urothelial Carcinoma treated with AEZS-108 that is being reported. Considering the generally poor outcome of progressive UC and the short survival of these patients, the effect of this drug in this patient has been remarkable. The phase one study is ongoing.
It could be the the trials for endometrial, breast, prostate,and ovarian cancers would show enough positive effects that they do no have to do the bladder trial at the moment since there would be overlap.. Also if AEZS-108 works in these, a bladder trial would be a lot easier and less expensive.
there is no way to predict Z160 outcome. It is to complex. Surprised about the Jason tweet. He will definitely get backlash from his bosses. He should of known better.
Selling Cetrotide to Merck Serono was a good thing. 2 patents for Cetrotide #6863891 and # 7605121 are to expire 0n 2/22/2014. To concentrate on AEZS-130 where the patents could expire in 2027 makes sense. When NDA is filed for AEZS-130 we will see a pop. Also AEZS-108 had a SPA with the FDA which is a declaration from the Food and Drug Administration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval. If results are good approval could come a lot faster that some mb posters state. If AEZS-108 works with endometrial cancer there is a good chance it will work with other cancers as well. The 42 million market cap for what AEZS has in it pipeline and cash is very low compared to other biotechs. Many have a higher market cap with a lot less. This company is doing a turnaround and smart money is buying at these levels. If you noticed the bid pattern lately you will know what I mean. A gap up is due soon.
Look for a least a 25% pop. That will only give it a 52 million market cap which is still peanuts compared to other biotechs. CC call next week will shed more light on this. But before cc call buy and make some money.